Medico Remedies Ltd

Medico Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Medico Remedies Ltd

₹ 55.7 -1.52%
30 Apr - close price
medicoremedies.com BSE: 540937 NSE: MEDICO
About

Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]

Key Points

Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments

Website BSE NSE
  • Market Cap ₹ 462 Cr.
  • Current Price ₹ 55.7
  • High / Low ₹ 79.8 / 34.8
  • Stock P/E 52.2
  • Book Value ₹ 6.69
  • Dividend Yield 0.00 %
  • ROCE 21.3 %
  • ROE 17.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has delivered good profit growth of 39.5% CAGR over last 5 years

Cons

  • Stock is trading at 8.32 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -3.04%
  • The company has delivered a poor sales growth of 8.21% over past five years.
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 103 to 125 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
30.13 32.28 33.14 40.46 38.85 27.99 31.47 42.36 29.77 41.32 30.80 39.35 39.49
28.21 29.64 33.32 37.32 35.46 24.82 29.01 39.29 27.04 36.67 27.98 36.94 36.38
Operating Profit 1.92 2.64 -0.18 3.14 3.39 3.17 2.46 3.07 2.73 4.65 2.82 2.41 3.11
OPM % 6.37% 8.18% -0.54% 7.76% 8.73% 11.33% 7.82% 7.25% 9.17% 11.25% 9.16% 6.12% 7.88%
0.23 0.74 1.60 1.55 0.86 0.04 0.31 0.96 0.27 0.58 0.29 0.68 1.43
Interest 0.20 0.13 0.17 0.17 0.20 0.21 0.17 0.18 0.22 0.25 0.18 0.21 0.28
Depreciation 0.44 0.88 0.59 0.66 0.74 0.73 0.71 0.71 0.72 0.74 0.75 0.75 0.76
Profit before tax 1.51 2.37 0.66 3.86 3.31 2.27 1.89 3.14 2.06 4.24 2.18 2.13 3.50
Tax % 33.11% 20.25% 43.94% 25.65% 32.33% 22.47% 29.63% 22.61% 30.10% 26.89% 27.06% 27.23% 25.14%
1.01 1.88 0.36 2.87 2.25 1.77 1.32 2.43 1.45 3.10 1.58 1.55 2.62
EPS in Rs 0.12 0.23 0.04 0.35 0.27 0.21 0.16 0.29 0.17 0.37 0.19 0.19 0.32
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
34 45 51 67 54 61 98 89 122 121 140 145 151
32 43 48 63 50 58 95 86 117 114 131 132 138
Operating Profit 1 2 3 4 4 3 3 3 5 7 10 13 13
OPM % 4% 5% 6% 5% 7% 6% 3% 3% 4% 6% 7% 9% 9%
0 0 0 0 0 1 2 2 1 2 4 2 3
Interest 0 1 1 1 1 2 1 1 1 1 1 1 1
Depreciation 0 1 1 1 1 1 2 2 2 2 3 3 3
Profit before tax 1 1 1 2 2 2 2 2 4 6 10 11 12
Tax % 40% 34% 28% 40% 4% 35% 28% 26% 30% 26% 28% 27%
0 1 1 1 2 1 2 2 3 5 7 8 9
EPS in Rs 0.21 0.25 0.25 0.35 0.25 0.15 0.19 0.20 0.31 0.58 0.87 1.00 1.07
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 12%
5 Years: 8%
3 Years: 6%
TTM: 15%
Compounded Profit Growth
10 Years: 29%
5 Years: 39%
3 Years: 47%
TTM: 27%
Stock Price CAGR
10 Years: %
5 Years: 72%
3 Years: 41%
1 Year: 23%
Return on Equity
10 Years: 11%
5 Years: 13%
3 Years: 17%
Last Year: 17%

Balance Sheet

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 1 1 2 2 3 4 4 4 4 17 17 17 17
Reserves 4 7 12 13 13 23 24 26 28 20 27 36 39
6 8 8 14 19 13 14 14 15 13 10 8 11
8 14 14 17 13 20 35 32 28 28 34 36 32
Total Liabilities 18 31 36 46 48 59 76 75 76 77 87 96 99
4 8 8 7 7 7 12 13 15 18 22 21 21
CWIP 0 0 0 0 3 4 1 2 0 0 0 0 0
Investments 1 0 1 1 0 0 0 0 1 0 1 2 0
14 23 27 38 39 48 63 60 59 59 64 73 78
Total Assets 18 31 36 46 48 59 76 75 76 77 87 96 99

Cash Flows

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-3 5 5 1 -11 6 8 3
-3 -5 -4 -3 -17 -2 -7 -3
6 -1 -1 3 18 -6 -2 -0
Net Cash Flow -0 -0 -0 0 -10 -2 -0 -1

Ratios

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 24 49 53 107 122 102 109 98 82 92 94 125
Inventory Days 61 81 76 63 96 125 74 99 58 76 69 54
Days Payable 89 139 122 106 112 147 149 143 100 113 108 105
Cash Conversion Cycle -4 -10 6 64 105 80 33 54 39 54 54 75
Working Capital Days 69 68 77 109 163 146 87 90 80 82 76 92
ROCE % 11% 10% 11% 10% 9% 8% 8% 10% 15% 21% 21%

Shareholding Pattern

Numbers in percentages

16 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
73.34% 73.34% 73.34% 73.34% 73.34% 73.34% 73.34% 73.34% 73.34% 73.34% 66.83% 63.79%
0.00% 0.00% 0.00% 0.53% 1.19% 1.11% 1.29% 0.29% 0.22% 0.22% 0.39% 0.11%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.74% 0.97% 0.97% 0.78% 0.01%
26.66% 26.65% 26.66% 26.15% 25.46% 25.55% 25.36% 25.63% 25.46% 25.47% 32.00% 36.08%
No. of Shareholders 5017781,7773,2875,0555,2646,05210,68512,90212,88714,10415,424

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • Jan 2024
    Transcript
    Notes
    PPT
  • Nov 2022
    Transcript
    Notes
    PPT